Bionomics Limited , a biopharmaceuticals company announces that it has entered into an exclusive Research Collaboration and Licence Agreement with Merck, known as MSD outside the United States and Canada, for its BNC375 research programme targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions.
Under the agreement, Merck will fund all research and development, including clinical development, and will be responsible for worldwide commercialisation of any products from the collaboration. Bionomics will receive upfront payments totalling US$20 million and is eligible to receive up to US$506 million for achievement of certain research and clinical development milestones and undisclosed royalties on any product sales.
“We are very excited to work with Merck to progress new therapies for cognitive impairment in conditions such as Alzheimer’s disease,” said Dr Deborah Rathjen, cief executive officer & managing director of Bionomics. “We believe that the combination of Bionomics’ innovative approach and technologies,within its ionX platform, has the potential to rapidly advance new treatments.”
"Bionomics continues to deliver on its business model that focuses on strategic partnering for the development and commercialisation of selected programmes within its pipeline,” Dr Rathjen added.“This significant agreement, our second with Merck, further validates our drug discovery platforms.”
“Merck is pleased to add a new scientific collaboration with Bionomics,” said Dr Rupert Vessey, head of Early Development and Discovery Sciences at Merck Research Laboratories. “Bionomics.’capabilities and overall expertise in discovery and characterisation of small molecules for this neuroscience target class is impressive.”
In July 2013, Bionomics announced an option and licence agreement with Merck to discover and develop novel small molecule candidates for the treatment of chronic pain, including neuropathic pain. Under the terms of that agreement, Merck has the option to exclusively license a compound from Bionomics for development and commercialisation.
BNC375 is a key compound from the Bionomics research programme licensed to Merck under this latest agreement. BNC375 and related compounds have displayed potent efficacy in animal cognitive impairment models.
Alzheimer’s is the most common type of dementia and thought to be caused by damage to nerve cells in the brain. Symptoms are characterised by a decline in memory or other thinking skills; itaffects a person’s everyday activities and is fatal. 1 in 9 Americans older than 65 years has Alzheimer’s disease (5 million people). It is the 6 th leading cause of death in the United States. By 2025 the number of Americans aged 65 and older with Alzheimer’s is forecast to rise 40% to 7.1 million (2014 Alzheimer’s disease, Alzheimer’s Association). More than 332,000 Australians suffer from Alzheimer’s disease.